Stage II CRC patients with high GAL expression had a lower 5-year overall survival (5-OS) and 5-year recurrence-free survival (5-RFS) than those with low GAL expression (5-OS: 30.3 vs. 82.3%, respectively, P<0.001; 5-RFS: 27.3 vs. 57.5%, P=0.006) (Fig. 2A and B). The gene discussed is GAL; the disease is colorectal carcinoma.